AMA Urges 340B Transparency, Expansion Of Program To More Providers

The American Medical Association is pushing for 340B reforms that would increase transparency in the drug pricing program, expand the Health Resources and Services Administration's authority over 340B and extend program eligibility to all practices that show a commitment to serving low-income patients. The proposed reforms are laid out in a resolution adopted by the country's largest physicians' lobby group at its recent annual meeting. The resolution also initially included a provision that said AMA supports discontinuing the use of...